HOOKIPA Pharma (HOOK) Stock Price, News & Analysis

Company Overview

HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapeutics designed to harness the body’s immune system to prevent and treat infectious diseases and cancer. Leveraging proprietary virus-like vesicle (VLV) and modified vaccinia Ankara (MVA) vector technology platforms, HOOKIPA engineers targeted immune responses by delivering antigens directly to antigen-presenting cells. Its lead programs include prophylactic and therapeutic vaccine candidates against cytomegalovirus (CMV) and human immunodeficiency virus (HIV), as well as investigational immuno-oncology products designed to stimulate tumor-specific immunity.

Since its founding in Vienna in 2009, HOOKIPA has advanced multiple programs into human clinical trials, forging collaborations with academic institutions and industry partners. The company operates research and development laboratories in Austria alongside clinical development and corporate functions in North America, reflecting its commitment to global vaccine innovation. Through preclinical studies and early-stage trials, HOOKIPA has demonstrated favorable safety profiles and immunogenicity, positioning its platforms for broader applications in both infectious disease prevention and therapeutic cancer interventions.

Central to HOOKIPA’s strategy is its VLV platform, which combines elements of live-attenuated vectors with the safety advantages of non-replicating systems. This approach enables robust T-cell and antibody responses without the risks associated with traditional live vaccines. The MVA vector platform further complements these efforts, offering a well-characterized backbone with a long history of clinical use. Together, these technologies underpin HOOKIPA’s pipeline diversification and long-term vision of creating next-generation immunotherapies.

HOOKIPA’s leadership team brings extensive expertise in virology, immunology and biopharmaceutical development. Through strategic partnerships, disciplined clinical execution and a pipeline spanning both preventive and therapeutic modalities, the company aims to address significant unmet needs in global health. With ongoing trials in Europe and the United States, HOOKIPA continues to advance toward regulatory milestones while exploring new indications that could benefit from its innovative vector platforms.

Key Stats

• Today's Range: $1.17 to $1.18
• 50-Day Range: $1.17 to $1.75
• 52-Week Range: $0.72 to $6.69
• Volume: 5,677 shs
• Average Volume: 81,583 shs
• Market Capitalization: $14.26 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.50
• Consensus Rating: Hold

HOOKIPA Pharma Stock Analysis - MarketRank™

HOOKIPA Pharma scored higher than 61% of companies evaluated by MarketBeat, and ranked 427th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

HOOKIPA Pharma has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

HOOKIPA Pharma has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for HOOKIPA Pharma are expected to decrease in the coming year, from ($1.75) to ($2.60) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of HOOKIPA Pharma is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of HOOKIPA Pharma is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

HOOKIPA Pharma has a P/B Ratio of 0.28. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.58% of the float of HOOKIPA Pharma has been sold short.

Short Interest Ratio / Days to Cover

HOOKIPA Pharma has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in HOOKIPA Pharma has recently decreased by 15.54%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

HOOKIPA Pharma does not currently pay a dividend.

Dividend Growth

HOOKIPA Pharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.58% of the float of HOOKIPA Pharma has been sold short.

Short Interest Ratio / Days to Cover

HOOKIPA Pharma has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in HOOKIPA Pharma has recently decreased by 15.54%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: N/A

News Sentiment

HOOKIPA Pharma has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.97 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for HOOKIPA Pharma this week, compared to 1 article on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, HOOKIPA Pharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.30% of the stock of HOOKIPA Pharma is held by insiders.

Percentage Held by Institutions

63.88% of the stock of HOOKIPA Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

HOOK Stock Analysis - Frequently Asked Questions

How have HOOK shares performed this year?

HOOKIPA Pharma's stock was trading at $2.01 at the beginning of 2025. Since then, HOOK stock has decreased by 41.8% and is now trading at $1.17.

How were HOOKIPA Pharma's earnings last quarter?

HOOKIPA Pharma Inc. (NASDAQ:HOOK) announced its earnings results on Thursday, May, 15th. The company reported ($1.23) earnings per share for the quarter, missing analysts' consensus estimates of ($0.61) by $0.62. HOOKIPA Pharma had a negative trailing twelve-month return on equity of 120.09% and a negative net margin of 785.66%.

When did HOOKIPA Pharma's stock split?

HOOKIPA Pharma shares reverse split on Wednesday, July 10th 2024.The 1-10 reverse split was announced on Wednesday, July 10th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 10th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did HOOKIPA Pharma IPO?

HOOKIPA Pharma (HOOK) raised $100 million in an initial public offering on Thursday, April 18th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets acted as the underwriters for the IPO and Kempen was co-manager.

How do I buy shares of HOOKIPA Pharma?

Shares of HOOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of HOOKIPA Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that HOOKIPA Pharma investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Pfizer (PFE), Advanced Micro Devices (AMD), Cabaletta Bio (CABA) and Novo Nordisk A/S (NVO).

Company Calendar

• Last Earnings: 5/15/2025
• Today: 7/16/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:HOOK
• CIK: 1760542
• Web: www.hookipapharma.com
• Phone: 431-890-6360
• Fax: 43-1890-636-0399
• Employees: 160
• Year Founded: N/A

Price Target and Rating

• Average Price Target for HOOKIPA Pharma: $4.50
• High Price Target: $7.00
• Low Price Target: $2.00
• Potential Upside/Downside: +284.6%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($5.85)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$43.50 million
• Net Margins: -785.66%
• Pretax Margin: -785.15%
• Return on Equity: -120.09%
• Return on Assets: -77.14%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.61
• Quick Ratio: 3.61

Sales & Book Value

• Annual Sales: $43.95 million
• Price / Sales: 0.32
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.25 per share
• Price / Book: 0.28

Miscellaneous

• Outstanding Shares: 12,190,000
• Free Float: 11,787,000
• Market Cap: $14.26 million
• Optionable: Optionable
• Beta: 0.89